Simplex Trading’s Ovid Therapeutics OVID Stock Holding History

Simplex Trading’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.16K	Sell	3,674 -27,929	-88%	-$49.9K	﹤0.01%	7524
2025 Q4	$51.5K	Sell	31,603 -355,909	-92%	-$548K	﹤0.01%	5629
2025 Q3	$503K	Buy	+387,512	New	+$336K	﹤0.01%	3814
2025 Q1	–	Sell	-590	Closed	-$363	–	9350
2024 Q4	$0	Sell	590 -3,905	-87%	-$4.37K	﹤0.01%	9333
2024 Q3	$5K	Buy	4,495 +2,112	+89%	+$2.21K	﹤0.01%	7639
2024 Q2	$1K	Buy	2,383 +1,150	+93%	+$3.2K	﹤0.01%	8521
2024 Q1	$3K	Buy	+1,233	New	+$4.13K	﹤0.01%	8287
2023 Q2	–	Sell	-422	Closed	-$1.43K	–	9672
2023 Q1	$1K	Buy	+422	New	+$1K	﹤0.01%	8740
2022 Q3	–	Sell	-99	Closed	-$207	–	10626
2022 Q2	$0	Buy	+99	New	+$239	﹤0.01%	10775
2021 Q2	–	Sell	-91,818	Closed	-$362K	–	10518
2021 Q1	$369K	Buy	91,818 +54,868	+148%	+$182K	﹤0.01%	3847
2020 Q4	$85K	Buy	+36,950	New	+$172K	﹤0.01%	5613

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Simplex Trading's OVID Position: Q1 2026 in Review

Simplex Trading reduced its Ovid Therapeutics (OVID) stake by 88% in Q1 2026, selling an estimated $49.9K and leaving 3,674 shares worth $8.16K. The position accounts for ﹤0.01% of the portfolio, ranked #7524.

Simplex Trading first reported a position in OVID in Q4 2020 and has held it in 11 quarters since. The position peaked at $503K in Q3 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Simplex Trading held 3,674 shares of Ovid Therapeutics worth $8.16K as of Q1 2026.
Simplex Trading sold 27,929 Ovid Therapeutics shares in Q1 2026, an estimated $49.9K.
Ovid Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7524 holding.
Simplex Trading first reported a position in Ovid Therapeutics in Q4 2020 and has held it in 11 quarters since.
Simplex Trading's Ovid Therapeutics position peaked at $503K in Q3 2025.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.